$1.77 Million in Sales Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
Equities analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report sales of $1.77 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $450,000.00 and the highest estimate coming in at $3.08 million. AVEO Pharmaceuticals reported sales of $430,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 311.6%. The firm is expected to announce its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year sales of $11.05 million for the current fiscal year, with estimates ranging from $3.11 million to $24.30 million. For the next financial year, analysts anticipate that the firm will report sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.
In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was acquired at an average price of $1.14 per share, with a total value of $4,956,522.78. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.40% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of AVEO. Two Sigma Securities LLC purchased a new position in AVEO Pharmaceuticals in the 4th quarter worth about $28,000. HCR Wealth Advisors purchased a new position in AVEO Pharmaceuticals in the 1st quarter worth about $28,000. Chicago Equity Partners LLC purchased a new stake in shares of AVEO Pharmaceuticals during the 4th quarter valued at about $32,000. Albion Financial Group UT purchased a new stake in shares of AVEO Pharmaceuticals during the 4th quarter valued at about $38,000. Finally, Excalibur Management Corp increased its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 40,000 shares during the last quarter. 28.31% of the stock is owned by institutional investors and hedge funds.
AVEO Pharmaceuticals stock traded down $0.06 during mid-day trading on Wednesday, reaching $0.76. The stock had a trading volume of 2,423,600 shares, compared to its average volume of 5,789,052. The stock has a market cap of $136.63 million, a price-to-earnings ratio of -4.00 and a beta of 1.26. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Article: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.